Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Allergic Rhinitis Market

ID: MRFR/Pharma/1018-CR
129 Pages
Nidhi Mandole
Last Updated: April 24, 2026

Allergic rhinitis market Research Report Information By Type (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, and Occupational Allergic Rhinitis), By Treatment (Antihistamines, Corticosteroids, Immunotherapy, Decongestants and others), By Route of Administration (Oral, and Nasal & Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Allergic Rhinitis Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type (USD Billion) | |
      1. 4.1.1 Seasonal Allergic Rhinitis | |
      2. 4.1.2 Perennial Allergic Rhinitis | |
      3. 4.1.3 Occupational Allergic Rhinitis |
    2. 4.2 Healthcare, BY Treatment (USD Billion) | |
      1. 4.2.1 Antihistamines | |
      2. 4.2.2 Corticosteroids | |
      3. 4.2.3 Immunotherapy | |
      4. 4.2.4 Decongestants | |
      5. 4.2.5 Others |
    3. 4.3 Healthcare, BY Route of Administration (USD Billion) | |
      1. 4.3.1 Oral | |
      2. 4.3.2 Nasal & Others |
    4. 4.4 Healthcare, BY Region (USD Billion) | |
      1. 4.4.1 North America | | |
        1. 4.4.1.1 US | | |
        2. 4.4.1.2 Canada | |
      2. 4.4.2 Europe | | |
        1. 4.4.2.1 Germany | | |
        2. 4.4.2.2 UK | | |
        3. 4.4.2.3 France | | |
        4. 4.4.2.4 Russia | | |
        5. 4.4.2.5 Italy | | |
        6. 4.4.2.6 Spain | | |
        7. 4.4.2.7 Rest of Europe | |
      3. 4.4.3 APAC | | |
        1. 4.4.3.1 China | | |
        2. 4.4.3.2 India | | |
        3. 4.4.3.3 Japan | | |
        4. 4.4.3.4 South Korea | | |
        5. 4.4.3.5 Malaysia | | |
        6. 4.4.3.6 Thailand | | |
        7. 4.4.3.7 Indonesia | | |
        8. 4.4.3.8 Rest of APAC | |
      4. 4.4.4 South America | | |
        1. 4.4.4.1 Brazil | | |
        2. 4.4.4.2 Mexico | | |
        3. 4.4.4.3 Argentina | | |
        4. 4.4.4.4 Rest of South America | |
      5. 4.4.5 MEA | | |
        1. 4.4.5.1 GCC Countries | | |
        2. 4.4.5.2 South Africa | | |
        3. 4.4.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 GlaxoSmithKline (GB) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Boehringer Ingelheim (DE) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Sanofi (FR) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 AstraZeneca (GB) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Novartis (CH) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Merck & Co. (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Allergan (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Bayer (DE) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Teva Pharmaceutical Industries (IL) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE |
    7. 6.4 US MARKET ANALYSIS BY TREATMENT |
    8. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    9. 6.6 CANADA MARKET ANALYSIS BY TYPE |
    10. 6.7 CANADA MARKET ANALYSIS BY TREATMENT |
    11. 6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    12. 6.9 EUROPE MARKET ANALYSIS |
    13. 6.10 GERMANY MARKET ANALYSIS BY TYPE |
    14. 6.11 GERMANY MARKET ANALYSIS BY TREATMENT |
    15. 6.12 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    16. 6.13 UK MARKET ANALYSIS BY TYPE |
    17. 6.14 UK MARKET ANALYSIS BY TREATMENT |
    18. 6.15 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    19. 6.16 FRANCE MARKET ANALYSIS BY TYPE |
    20. 6.17 FRANCE MARKET ANALYSIS BY TREATMENT |
    21. 6.18 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    22. 6.19 RUSSIA MARKET ANALYSIS BY TYPE |
    23. 6.20 RUSSIA MARKET ANALYSIS BY TREATMENT |
    24. 6.21 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    25. 6.22 ITALY MARKET ANALYSIS BY TYPE |
    26. 6.23 ITALY MARKET ANALYSIS BY TREATMENT |
    27. 6.24 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    28. 6.25 SPAIN MARKET ANALYSIS BY TYPE |
    29. 6.26 SPAIN MARKET ANALYSIS BY TREATMENT |
    30. 6.27 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    31. 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    32. 6.29 REST OF EUROPE MARKET ANALYSIS BY TREATMENT |
    33. 6.30 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    34. 6.31 APAC MARKET ANALYSIS |
    35. 6.32 CHINA MARKET ANALYSIS BY TYPE |
    36. 6.33 CHINA MARKET ANALYSIS BY TREATMENT |
    37. 6.34 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    38. 6.35 INDIA MARKET ANALYSIS BY TYPE |
    39. 6.36 INDIA MARKET ANALYSIS BY TREATMENT |
    40. 6.37 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    41. 6.38 JAPAN MARKET ANALYSIS BY TYPE |
    42. 6.39 JAPAN MARKET ANALYSIS BY TREATMENT |
    43. 6.40 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    44. 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    45. 6.42 SOUTH KOREA MARKET ANALYSIS BY TREATMENT |
    46. 6.43 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    47. 6.44 MALAYSIA MARKET ANALYSIS BY TYPE |
    48. 6.45 MALAYSIA MARKET ANALYSIS BY TREATMENT |
    49. 6.46 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    50. 6.47 THAILAND MARKET ANALYSIS BY TYPE |
    51. 6.48 THAILAND MARKET ANALYSIS BY TREATMENT |
    52. 6.49 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    53. 6.50 INDONESIA MARKET ANALYSIS BY TYPE |
    54. 6.51 INDONESIA MARKET ANALYSIS BY TREATMENT |
    55. 6.52 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    56. 6.53 REST OF APAC MARKET ANALYSIS BY TYPE |
    57. 6.54 REST OF APAC MARKET ANALYSIS BY TREATMENT |
    58. 6.55 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
    60. 6.57 BRAZIL MARKET ANALYSIS BY TYPE |
    61. 6.58 BRAZIL MARKET ANALYSIS BY TREATMENT |
    62. 6.59 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    63. 6.60 MEXICO MARKET ANALYSIS BY TYPE |
    64. 6.61 MEXICO MARKET ANALYSIS BY TREATMENT |
    65. 6.62 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    66. 6.63 ARGENTINA MARKET ANALYSIS BY TYPE |
    67. 6.64 ARGENTINA MARKET ANALYSIS BY TREATMENT |
    68. 6.65 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT |
    71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    72. 6.69 MEA MARKET ANALYSIS |
    73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT |
    75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT |
    78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    79. 6.76 REST OF MEA MARKET ANALYSIS BY TYPE |
    80. 6.77 REST OF MEA MARKET ANALYSIS BY TREATMENT |
    81. 6.78 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
    83. 6.80 RESEARCH PROCESS OF MRFR |
    84. 6.81 DRO ANALYSIS OF HEALTHCARE |
    85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
    88. 6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    89. 6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    90. 6.87 HEALTHCARE, BY TREATMENT, 2024 (% SHARE) |
    91. 6.88 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion) |
    92. 6.89 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    93. 6.90 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
    94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    95. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY TREATMENT, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    126. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Seasonal Allergic Rhinitis
  • Perennial Allergic Rhinitis
  • Occupational Allergic Rhinitis

Healthcare By Treatment (USD Billion, 2025-2035)

  • Antihistamines
  • Corticosteroids
  • Immunotherapy
  • Decongestants
  • Others

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Nasal & Others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions